A New Approach to Psychiatric Drug Approval in Europe-Reference-Cited by-同舟云学术

A New Approach to Psychiatric Drug Approval in Europe

Published:2013-10-15 Issue:10 Volume:10 Page:e1001530
ISSN:1549-1676
Container-title:PLoS Medicine
language:en
Short-container-title:PLoS Med

Author:

Barbui Corrado,Bighelli Irene

Publisher

Public Library of Science (PLoS)

Subject

General Medicine

Reference34 articles.

1. What is the European Medicines Agency?;I Bighelli;Epidemiol Psychiatr Sci,2012

2. Number of patients studied prior to approval of new medicines: a database analysis;RG Duijnhoven;PLoS Med,2013

3. EMA must improve the quality of its clinical trial reports;C Barbui;BMJ,2011

4. Regulatory science in Europe: the case of schizophrenia trials;C Barbui;Lancet,2013

5. European Medicines Agency (2010) Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available. European Medicines Agency EMA/759784/2010.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Requesting conflicts of interest declarations from the European Medicines Agency: 3-year follow-up status;Epidemiology and Psychiatric Sciences;2024

2. Ground-breaking change to the mental health section of the WHO Model List of Essential Medicines: implications for low- and middle-income countries;Epidemiology and Psychiatric Sciences;2024

3. Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs;European Neuropsychopharmacology;2022-07

4. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations;Epidemiology and Psychiatric Sciences;2021

5. Placebo—To be or not to be? Are there really alternatives to placebo-controlled trials?;European Neuropsychopharmacology;2020-03